GeneralHealthMedicineNeuroscienceWorld
Researchers suggest a less traditional assessment could help flag dementia earlier
2019 ended on a high note for Alzheimer’s research.
Just before the new year, the pharma company Biogen released clinical trial data suggesting that its drug, aducanumab, could successfully remove amyloid from the brain—one of the trademark proteins behind Alzheimer’s disease.
- Kathleen Ellen Foley
- Quartz
Understandably, the drug has gotten a lot of attention: It’s been a bleak few decades for Alzheimer’s research, whose history is …